AGRX News and Press, Agile Therapeutics Inc. From 12/21/22

(NewsDirect) Biotech company Agile Therapeutics Inc. (NASDAQ: AGRX) began selling its contraceptive patch in 2021, and the company is pursuing positive cash flow by the end of 2023. The Princeton, New Jersey-based company’s Twirla patch gives women the choice to not take a birt...

PRINCETON, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it will participate in the RHK Capital Disruptive Growth Conference being held in the offices of Reed Smith in New York, NY on December 5-6, 2022. Chairma...

(NewsDirect) Agile Therapeutics Inc. (NASDAQ: AGRX) is on a journey to fulfill the unmet health needs of women with products designed to provide them with contraceptive options. The company’s product and product candidates are designed to provide women with contraceptive ...

--News Direct-- Agile Therapeutics Inc. (NASDAQ: AGRX) is on a journey to fulfill the unmet health needs of women with products designed to provide them with contraceptive options. The company’s product and product candidates are designed to provide women with contracepti...

Shares of micro-cap women's healthcare company Agile Therapeutics ( NASDAQ: AGRX ) fell 16.6% to $0.27 in Tuesday mid-day trading, a day after it reported mixed Q3 results. It is worth noting that the stock had advanced nearly 20% in the previous session ahead of t...

Agile Therapeutics, Inc. (AGRX) Q3 2022 Results Conference Call November 07, 2022 04:30 PM ET Company Participants Matthew Riley - Head of Investor Relations Alfred Altomari - Chairman and Chief Executive Officer Amy Welsh - Chief Commercial Officer Jason But...

Agile Therapeutics press release ( NASDAQ: AGRX ): Q3 GAAP EPS of -$0.53 misses by $0.23 . Revenue of $3M (+132.6% Y/Y) beats by $0.67M . For further details see: Agile Therapeutics GAAP EPS of -$0.53 misses by $0.23, revenue of $3M beats by $0.67M

Net Revenue Increased 43% from Second Quarter 2022 Largest Quarter-over-Quarter Increase in Net Revenue Achieved by Agile Non-Retail Channel Twirla Cycles Grew 361% from Second Quarter 2022 Company Expects Business Plan Can Deliver Additional Growth in the Fourth Q...

PRINCETON, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report third quarter 2022 financial results after the market close on Monday, November 7, 2022. Following the release, the Company will...

(NewsDirect) From Evofem Biosciences Inc. ’s (OTCMKTS: EVFM) Phexxi vaginal gel contraceptive to Dare Bioscience Inc. ’s (NASDAQ: DARE) Ovaprene, an investigational hormone-free monthly intravaginal contraceptive, the market is never in short supply of birth contro...